instrumentation analytical services oem applications consultancy partnerships

Latest news from deltaDOT

London, UK, 30 January 2012 - deltaDOT Ltd., announced today signing of a distribution agreement with Kyokuto Boeki Kaisha Ltd. of Tokyo, Japan which covers the promotion and sales of deltaDOT’s analytical instrument systems in Japan.
 

London, UK, 27 January 2012 - deltaDOT Scientist gains Ph.D from Imperial College London.  deltaDOT Ltd, announced today that Fiona Pereira, completed all stages of her Ph.D in Label Free Intrinsic Imaging and continuous and segmented flow Microfluidics, sponsored by deltaDOT Ltd.
(more in this pdf file) 

 

London, UK, 15 September 2011 -  deltaDOT attended the prestigious JAIMA (Japan Analytical Instruments Manufacturers Association Expo 2011 at Makuhari Messe, Japan in September.
(more in this pdf file)
 

London, UK, 27 May 2011 - deltaDOT has been selected as a partner in the US National Biosecurity Center to advise on and to provide analytical technology for this new consortium. This is a major achievement for the company as the consortium includes the world leaders from pharmaceutical and life sciences industry sectors. “This team represents some of the world’s finest scientists, engineers, corporations, and educators in the field” comments Dr. Brett Giroir, Vice Chancellor  for Strategic Initiatives at the A&M System and the Project Director.
(more in this pdf file) 

 

London, UK, 16 May 2011- Mayor of London congratulates deltaDOTBoris Johnson, Mayor of London, was shown deltaDOT’s Peregrine-1 instrument as part of the Business Bootcamp launch held at the British Library.
(more in this pdf file

 

 

.

Label Free Process Analytical Technology

deltaDOT applies molecular biology and particle physics technology to the needs of biomolecular separation, including protein, DNA and RNA analysis.

The company has a strong proprietary position and extensive expertise in instrumentation, molecular biology, microfluidics, automation, computing and analysis which will contribute to improvements in knowledge, profitability and process time throughout drug discovery and general life sciences research.